DiaMedica to Present at InvestMNt Conference on August 6, 2014

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
primarily focused on the development of novel, first-in-class therapies for
metabolic disorders, kidney dysfunction and orphan diseases, announced today
that the Company will present at the 2014 InvestMNt conference sponsored by CFA
Society Minnesota. 


The all-day event will take place August 6 at the University of St. Thomas in
downtown Minneapolis. The Company will present at 3:45 p.m. CT. 


A total of 60 companies from the Upper Midwest and elsewhere are participating
in the conference, which is sponsored by the 1,200-member CFA Society and
financially supported by more than 25 institutional investment firms and
corporate sponsors. For more information and to register, visit
http://investmnt.org.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company primarily focused on the development of novel,
first-in-class therapies for metabolic disorders, kidney dysfunction and orphan
diseases. DiaMedica's lead clinical stage product, DM199, recombinant human
tissue kallikrein-1 protein ("rhKLK-1"), is a novel, first-in-class, therapeutic
for the treatment of diabetes mellitus and associated complications. DiaMedica
also is developing DM204, a monoclonal antibody program, for glucose control and
cardiovascular complications in type 2 diabetes and a companion diagnostic in
vitro assay, DMDx, utilizing the detection of tissue kallikrein-1 protein
("KLK-1") as a potential biomarker in human urine to identify diabetic kidney
disease patients who are most likely to respond to a therapeutic regimen that
includes DM199. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


About InvestMNt

Now in its 3rd year, InvestMNt is a one-day conference developed by
institutional investors at mutual funds, private money management firms,
retirement plan sponsors and other wealth management entities. Last year's event
featured C-level executives from 48 presenting companies, plus more than 200
one-on-one meetings with senior management. More than 350 people attended last
year's event, which was conceived and implemented by the CFA Society of
Minnesota.


About CFA Society of Minnesota

Founded in 1952, the CFA Society of Minnesota is one of the oldest chapters of
the prestigious CFA Institute, issuer of the Chartered Financial Analyst
designation. The CFA Society of Minnesota is the 21st largest society of
analysts among the 143 member societies and affiliates worldwide. For 60 years,
CFA Minnesota has played a vital role within the Twin Cities investment
community.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, including the intended use of the net proceeds of the Offering,
should be considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and
words of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future events and are
subject to certain risks and uncertainties as contained in DiaMedica's filings
with Canadian securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. DiaMedica undertakes no obligation, and does
not intend, to update, revise or otherwise publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof, or to reflect the occurrence of any unanticipated events, unless
required by law. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these expectations will
materialize. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this press
release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
John Savage
Chief Financial Officer
763-270-0603
[e-mail]